Value for money of medicine sampling and quality testing: evidence from Indonesia.

IF 7.1 2区 医学 Q1 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH
Sara Valente de Almeida, Katharina Hauck, Sarah Njenga, Yunita Nugrahani, Ayu Rahmawati, Rahmi Mawaddati, Stanley Saputra, Amalia Hasnida, Elizabeth Pisani, Yusi Anggriani, Adrian Gheorghe
{"title":"Value for money of medicine sampling and quality testing: evidence from Indonesia.","authors":"Sara Valente de Almeida, Katharina Hauck, Sarah Njenga, Yunita Nugrahani, Ayu Rahmawati, Rahmi Mawaddati, Stanley Saputra, Amalia Hasnida, Elizabeth Pisani, Yusi Anggriani, Adrian Gheorghe","doi":"10.1136/bmjgh-2024-015402","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Substandard and falsified medicines (SFMs) are a public health concern of global importance. Postmarket surveillance in the form of medicine sampling and quality testing can prevent and detect SFM, however, there is remarkably scarce evidence about the cost and value for money of these activities: how much do they cost and how effective are they in detecting SFM?</p><p><strong>Methods: </strong>Between February and October 2022, Systematic Tracking of At Risk Medicines (STARmeds) collected and analysed for quality 1274 samples of 5 medicines from physical and online retail outlets in 7 Indonesian districts. We collated data on the resources consumed by STARmeds, related to all stages of medicines sampling and quality testing including design, fieldwork and laboratory analysis. We used activity-based costing principles to calculate the financial and economic cost of medicine quality surveillance from the perspective of a hypothetical medicines' regulator. We calculated the cost per day and per week of fieldwork, per sample collected and per substandard sample. We used bootstrapping to capture uncertainty in the number of samples collected, by seller location type (urban, rural and online).</p><p><strong>Results: </strong>The total cost of sampling and testing medicines from the market was US$712 964 (current 2022 values). Laboratory costs represented the largest share (70%), followed by other direct costs (12%) and indirect costs (7%). On average, it costs STARmeds US$479 (95% CI US$462 to US$516) to collect one medicine sample and US$5990 (95% CI US$5601 to US$6258) to identify one substandard sample.</p><p><strong>Conclusion: </strong>Our findings bring urgently needed and novel information on the cost and value for money of medicine quality surveillance. These may support planning and budgeting of the Indonesian pharmaceutical regulator, but also of regulators and researchers elsewhere, particularly in low-income and middle-income settings, as well as international organisations with health regulation and quality of care remits.</p>","PeriodicalId":9137,"journal":{"name":"BMJ Global Health","volume":"9 9","pages":""},"PeriodicalIF":7.1000,"publicationDate":"2024-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11429347/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMJ Global Health","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1136/bmjgh-2024-015402","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Substandard and falsified medicines (SFMs) are a public health concern of global importance. Postmarket surveillance in the form of medicine sampling and quality testing can prevent and detect SFM, however, there is remarkably scarce evidence about the cost and value for money of these activities: how much do they cost and how effective are they in detecting SFM?

Methods: Between February and October 2022, Systematic Tracking of At Risk Medicines (STARmeds) collected and analysed for quality 1274 samples of 5 medicines from physical and online retail outlets in 7 Indonesian districts. We collated data on the resources consumed by STARmeds, related to all stages of medicines sampling and quality testing including design, fieldwork and laboratory analysis. We used activity-based costing principles to calculate the financial and economic cost of medicine quality surveillance from the perspective of a hypothetical medicines' regulator. We calculated the cost per day and per week of fieldwork, per sample collected and per substandard sample. We used bootstrapping to capture uncertainty in the number of samples collected, by seller location type (urban, rural and online).

Results: The total cost of sampling and testing medicines from the market was US$712 964 (current 2022 values). Laboratory costs represented the largest share (70%), followed by other direct costs (12%) and indirect costs (7%). On average, it costs STARmeds US$479 (95% CI US$462 to US$516) to collect one medicine sample and US$5990 (95% CI US$5601 to US$6258) to identify one substandard sample.

Conclusion: Our findings bring urgently needed and novel information on the cost and value for money of medicine quality surveillance. These may support planning and budgeting of the Indonesian pharmaceutical regulator, but also of regulators and researchers elsewhere, particularly in low-income and middle-income settings, as well as international organisations with health regulation and quality of care remits.

药品抽样和质量检测的性价比:印度尼西亚的证据。
背景:假冒伪劣药品(SFMs)是一个具有全球重要性的公共卫生问题。以药品抽样和质量检测为形式的市场后监测可以预防和检测 SFM,然而,有关这些活动的成本和性价比的证据却非常缺乏:它们的成本是多少,它们在检测 SFM 方面的效果如何?2022 年 2 月至 10 月间,"高危药品系统追踪"(STARmeds)从印度尼西亚 7 个地区的实体零售店和网上零售店收集了 1274 份 5 种药品样本,并对其质量进行了分析。我们整理了 STARmeds 所消耗资源的相关数据,这些数据涉及药品采样和质量检测的各个阶段,包括设计、实地考察和实验室分析。我们采用基于活动的成本核算原则,从假定的药品监管机构的角度计算药品质量监控的财务和经济成本。我们计算了每一天和每一周的现场工作成本、每个采集样本的成本以及每个不合格样本的成本。我们使用引导法来捕捉按销售商地点类型(城市、农村和在线)划分的样本采集数量的不确定性:从市场上采样和检测药品的总成本为 712 964 美元(2022 年现值)。其中实验室成本所占比例最大(70%),其次是其他直接成本(12%)和间接成本(7%)。平均而言,STARmeds 收集一份药品样本的成本为 479 美元(95% CI 为 462 美元至 516 美元),发现一份不合格样本的成本为 5990 美元(95% CI 为 5601 美元至 6258 美元):我们的研究结果为药品质量监测的成本和性价比提供了急需的新信息。这些信息不仅有助于印尼药品监管机构的规划和预算编制,也有助于其他地方的监管机构和研究人员,尤其是低收入和中等收入国家的监管机构和研究人员,以及负责卫生监管和医疗质量的国际组织的规划和预算编制。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
BMJ Global Health
BMJ Global Health Medicine-Health Policy
CiteScore
11.40
自引率
4.90%
发文量
429
审稿时长
18 weeks
期刊介绍: BMJ Global Health is an online Open Access journal from BMJ that focuses on publishing high-quality peer-reviewed content pertinent to individuals engaged in global health, including policy makers, funders, researchers, clinicians, and frontline healthcare workers. The journal encompasses all facets of global health, with a special emphasis on submissions addressing underfunded areas such as non-communicable diseases (NCDs). It welcomes research across all study phases and designs, from study protocols to phase I trials to meta-analyses, including small or specialized studies. The journal also encourages opinionated discussions on controversial topics.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信